
RECEIVED **CENTRAL FAX CENTER**

MAY 3 1 2005

FAX



GlaxoSmithKline Glaxo Wellcome Inc.

PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

Tel: 919 483 2100 www.gsk.com

Serial No.: 10/502,261 Date: July 22, 2004 Applicant: Alvaro et al.

Title: PIPERIDINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHYKININS

Attached: Supplemental IDS PTO 1449 1 Reference Certificate of Transmission by Facsimile

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Supplemental IDS is being facsimile transmitted to the United States Patent and Trademark Office (Fax, No. 703-872-9306) on May 31, 2005

Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

P14748USW

MAY 3 1 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alvaro et al.

Serial No.:

10/502,261

Group Art Unit:

File Date:

July 22, 2004

Examiner:

For:

Piperidine Derivatives And Their Use As Antagonists of Tachykinins

Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[] C [] A st	copies of the references are enclosed: copies of the references were submitted in parent application
A.	[X] OR	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	II	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filling of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan

Registration No. 38,181

Date: 3/May 2005
GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

Page 1 of 1

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT SERIAL NO. FILING DATE July 22, 2004 APPLICANT Alvaro et al. GROUP 1615 EXAMINER E. Bernhardt	
APPLICANT Alvaro et al. GROUP 1615	
GROUP 1615	
EXAMINER F. Rombardt	
ATTORNEY DOCKET NO. PI4748USW	
U.S. PATENT DOCUMENTS	
	ng Date propriate
Continue on page FOREIGN PATENT DOCUMENTS	
	ıslation
Number Date Country Class Subclass Yes	
	
Continue on page	
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	
Pacher, P., et al. "Review of Cardiovascular Effects of Fluoxetine, A Selective Serotonine Rcuptake In Compared to Tricyclic Antidepressants." Current Medicinal Chemistry, 5, 381-390, 1998.	hibitor,
Continue on page	
EXAMINER DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant	<u> </u>